Peripheral Vascular Effects of Insulin in Obesity

Plain-language guide to NCT07874945: early phase 1 non-randomized trial of Insulin (regular human), insulin resistance, prediabetes & type 2 diabetes, 64 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07874945
Phase: early phase 1
Status: not yet recruiting
Start: 2026-12-01
Completion (planned or actual): 2031-06
Participants: 64 (estimated)
Design: non-randomized, open label (everyone knows who gets what), basic_science
Conditions studied: Obesity (BMI>30); Insulin Resistance
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered early phase 1 trial tested Insulin (regular human) for insulin resistance, prediabetes & type 2 diabetes.

Successful completion of this project will advance their understanding of the role sympathetic nervous system overactivity plays in driving skeletal muscle malperfusion during hyperinsulinemia and consequently impaired glucose uptake in obesity.

It had two arms (groups): Healthy normal weight adults (experimental) and Individuals with obesity and comorbid IR (experimental).

Healthy normal weight adults.

Individuals with obesity and comorbid insulin resistance.

The registry classes the interventions as drug.

Who Took Part

64 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: BMI 30-45 kg/m2. Waist circumference ≥102 cm (men) or ≥88 cm (women). BMI 18-25 kg/m2. Waist circumference \<94 cm (men) and \<80 cm (women).

The full record lists 6 inclusion and 13 exclusion criteria; among the exclusions: pregnancy, breastfeeding; unable to provide consent; diabetes or polycystic ovarian syndrome.

How the Study Was Run

It was run as a non-randomized, parallel-group and open-label study.

Groups ran in parallel: each of the insulin resistance, prediabetes & type 2 diabetes participants stayed in one arm throughout.

Being open-label, the Insulin (regular human) study did not mask who received what.

It started in 2026-12-01 with completion listed for 2031-06.

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): Forearm blood flow (time frame: 5-minute resting average).

What This Means in Plain Language

Put simply, this is a early phase 1, non-randomized trial of Insulin (regular human) in 64 people with insulin resistance, prediabetes & type 2 diabetes.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin (regular human) compound page, Insulin resistance, prediabetes & type 2 diabetes research.

Our Notes on the Compound

Insulin (regular human): The 51-amino-acid pancreatic hormone that lowers blood glucose; this page covers regular (short-acting) insulin studied in human trials.

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.